Phase I study of selinexor, ixazomib and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma

Selinexor, an orally bioavailable, first in class selective inhibitor of nuclear export (XPO1), was FDA approved in combination with dexamethasone for penta-refractory multiple myeloma patients in July 2019. The FDA approval was based on results from 83 patients on the Phase 2b STORM study that showed an ORR of 25% and a median duration of response of 3.8 months (1). Selinexor has been combined with bortezomib (2) and carfilzomib (3). Based on early results suggesting possible synergistic activity between selinexor and proteasome inhibitors, we designed a Phase I study to evaluate an all-oral combination therapy using the selective inhibitor of nuclear export (XPO1), selinexor, together with ixazomib and dexamethasone (SId) for patients with relapsed and/or refractory multiple myeloma.

Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2019 Category: Hematology Authors: Meghan Salcedo, Nikoletta Lendvai, Donna Mastey, Julia Schlossman, Malin Hultcrantz, Neha Korde, Sham Mailankody, Alexander Lesokhin, Hani Hassoun, Eric Smith, Urvi Shah, Victoria Diab, Kelly Werner, Heather Landau, Oscar Lahoud, Pamela Drullinsky, Gunjan Tags: Letter to the Editor Source Type: research